Gå direkt till innehåll

Pressmeddelande -

2005 first-quarter net sales growth ahead of world pharmaceutical

market growth1 at 11.9%2 on a comparable basis Strong growth in adjusted EPS3: up 27.7%2 at 1.06 euros per share Sanofi-aventis on track to meet 2005 guidance The consolidated statement of income of sanofi-aventis for the first quarter of 2005, presented in Appendix 4, shows net income of 531 million euros and is impacted by the accounting treatment of the combination with Aventis and by restructuring charges in a total amount of 884 million euros. The combination with Aventis having taken place on August 20, 2004, the scope of consolidation for 2004 is not directly comparable with that for 2005. To give a better representation of the business performance of the Group, we have decided to publish and comment an adjusted3 consolidated statement of income for the first quarter of 2005 (and to compare it with the adjusted pro forma3 statement of income for the first quarter of 2004). Adjusted net income reached 1 415 million euros versus 1 103 million euros in Q1 2004. All figures in this press release have been prepared using international financial reporting standards (IFRS). FIRST QUARTER 2005 • Net sales: 6,417 million euros, up 8.4% (11.9% on a comparable basis3) 18.6% comparable-basis growth for the top 15 products 3.0% comparable-basis growth for the rest of the portfolio • Developed sales3: 7,073 million euros, up 11.7% on a comparable basis • 27.9% growth in adjusted operating income – current • 28.3% growth in adjusted net income to 1,415 million euros • 27.7% increase in adjusted EPS to 1.06 euros (vs. 0.83 euros for the first quarter of 2004). Commenting on first quarter results, Chairman and CEO, Jean-François Dehecq, stated “In my view, these results are highly promising, and make us even more confident that our full-year guidance will be met. They reflect the soundness of the strategy we unveiled when the Group was formed, and the huge contribution of everyone at sanofi-aventis to ensure rapid delivery of the resources and synergies generated by the merger”. Full report attached. Senior Vice President, Corporate Communications: Nicole Cranois - Vice President, Media Relations: Jean-Marc Podvin Tel.:+33 1.53.77.42.23 - Fax: +33 1.53.77.42.65 - 174, avenue de FRANCE - 75013 Paris - France - www.sanofi-aventis.com

Ämnen

Kontakter

Klara Kämpfer

Klara Kämpfer

Presskontakt Communications Business Partner (föräldraledig t.o.m. 08/2024)

Lovisa Fasth

Presskontakt Communications Business Partner

Sanofi är ett av världens ledande läkemedelsföretag

Sanofi är ett globalt, innovativt läkemedelsföretag

Sanofi
Franzéngatan 6
112 51 Stockholm
Sverige